Close Menu

NEW YORK – Biopharma company Epizyme said on Friday that its new drug application for the accelerated approval of tazemetostat (Tazverik) to treat patients with relapsed or refractory follicular lymphoma was accepted by the US Food and Drug Administration. The intended use will be for patients who have previously received at least two lines of therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.